ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Our lead candidate, BPZE1, is the most advanced next generation pertussis vaccine, having completed two Phase 2 clinical trials. ILiAD Biotechnologies, LLC is a registered Delaware company founded in 2012.